NuCana Soars as FDA Fast Tracks Potential Drug for Biliary Tract
By Dhirendra Tripathi
Investing.com – NuCana stock (NASDAQ:) climbed 22% in Wednesday’s premarket trading as the Food and Drug Administration fast-tracked the company’s experimental drug for treatment of biliary tract cancer.
The drug, acelarin, is currently being evaluated in a phase-III study for the first-line treatment of patients.
The FDA’s announcement means that company and regulator will now stay in constant touch throughout the entire drug development and review process. This will ensure quick resolution of questions and issues to eventually result in earlier drug approval and access by patients, assuming the drug meets FDA norms.
A drug is fast tracked when no previous treatment exists or when the proposed solution has proven to be better than the available therapy.
The biliary tract comprises the gallbladder and interconnecting ducts responsible for the transport of bile from the liver to the gallbladder and small intestine. Approximately 178,000 new cases of biliary tract cancer are diagnosed each year worldwide, with more than 18,000 of those diagnoses in the U.S.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Read More: NuCana Soars as FDA Fast Tracks Potential Drug for Biliary Tract